# Rafael Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Rafael Holdings, Inc.). ## Overview Rafael Holdings, Inc. is a U.S.-based biotechnology and life sciences holding company focused on developing pharmaceuticals and medical devices through a portfolio of controlled and minority-owned subsidiaries. Its core assets include Trappsol® Cyclo™, a clinical-stage therapy for Niemann-Pick Disease Type C1, along with interests in cancer therapeutics, orthopedic devices, and an infusion-technology business. The company also retains a small real estate interest in Jerusalem, Israel. ## Products & services • Trappsol® Cyclo™ clinical-stage pharmaceutical development • Cyclodextrin products for research and related sales • Cancer therapeutics and metabolism-based drug development • Orthopedic medical device development for minimally invasive surgery • Infusion technology and Unlokt™-based manufacturing applications • Commercial real estate interest in Jerusalem - **Clinical-stage pharmaceuticals** (55%) — Development of Trappsol® Cyclo™ and other drug candidates for rare disease and oncology. - **Research product sales** (20%) — Sales of cyclodextrin products and related research materials used by laboratories and manufacturers. - **Medical devices** (5%) — Orthopedic-focused devices and instruments intended to support minimally invasive procedures. - **Infusion technology** (10%) — Technology and licensing activities tied to Unlokt™ and related manufacturing applications. - **Real estate** (10%) — Residual ownership interest in a commercial building in Jerusalem, Israel. - Trappsol® Cyclo™ clinical-stage pharmaceutical development - Cyclodextrin products for research and related sales - Cancer therapeutics and metabolism-based drug development - Orthopedic medical device development for minimally invasive surgery - Infusion technology and Unlokt™-based manufacturing applications - Commercial real estate interest in Jerusalem ## Customers Customers include research buyers of cyclodextrin products, clinical and commercial partners in pharmaceutical development, and manufacturers using Day Three's technology applications. The healthcare portfolio also serves patients indirectly through drug development programs and hospitals or surgeons through medical device commercialization. A small number of customers account for a large share of revenue, especially in the research-product stream. - **Research product customers** (primary) — Buy cyclodextrin products for research purposes and related applications; they value product availability and supply continuity. - **Clinical development stakeholders** (primary) — Include trial sites, collaborators, and future commercial partners supporting Trappsol® Cyclo™ and other drug candidates. - **Medical device users and distributors** (secondary) — Hospitals, surgeons, and channel partners that would use or distribute orthopedic instruments for minimally invasive procedures. - **Manufacturing and technology customers** (secondary) — Third-party manufacturers using Day Three's technology to improve product formulations and process outcomes. - **Real estate counterparties** (emerging) — Tenants or users associated with the Jerusalem commercial building interest. - Research laboratories buying cyclodextrins for scientific use - Pharmaceutical and biotech stakeholders in rare-disease development - Manufacturers using Unlokt™-based infusion or ingredient technology - Hospitals, surgeons, and distributors for orthopedic devices - Patients are the end beneficiaries of the drug-development pipeline ## Geography Rafael Holdings is headquartered in Newark, New Jersey, and its operating footprint spans the United States, Israel, and other markets tied to suppliers and clinical or manufacturing activity. The company’s portfolio includes a commercial building interest in Jerusalem and product sourcing relationships in the U.S., Japan, China, and Europe. That mix creates exposure to cross-border regulation, supply chains, and currency movements. - **United States** (60%) — Primary headquarters, operating base, and major supplier/customer market - **Israel** (20%) — Includes the remaining commercial real estate asset in Jerusalem - **Asia** (10%) — Supplier and manufacturing exposure, including Japan and China - **Europe** (10%) — Supplier and commercial exposure across European markets - Headquartered in Newark, New Jersey, United States - Commercial building interest located in Jerusalem, Israel - Product sourcing from the U.S., Japan, China, and Europe - Clinical and development activities span multiple jurisdictions - Cross-border operations create FX and regulatory exposure ## Strategy The company’s central strategy is to advance Trappsol® Cyclo™ through pivotal clinical development and, if successful, move toward regulatory approval and commercialization. It also seeks to preserve optionality through majority and minority investments in clinical-stage pharmaceuticals, medical devices, and technology-enabled businesses while concentrating resources on core assets. Opportunistic investments in high-unmet-need therapeutics remain part of the portfolio approach. - **Complete Trappsol® Cyclo™ clinical development** (short-term) — The lead asset is the main value driver and the clearest path to future commercialization. - **Focus capital on core healthcare holdings** (medium-term) — The company manages multiple subsidiaries and needs to direct resources toward the most promising programs. - **Build value through selective strategic investments** (long-term) — The holding-company structure allows participation in additional therapeutics and device opportunities. - Advance Trappsol® Cyclo™ through pivotal Phase 3 development - Prepare for regulatory filing and eventual commercialization - Concentrate resources on core healthcare assets - Maintain optionality through portfolio investments - Pursue opportunities in high unmet medical need areas ## Risks Rafael Holdings is exposed to clinical, regulatory, financing, and concentration risks typical of early-stage biotech and medical-device businesses. Its revenue base is narrow, dependent on a small number of customers and third-party suppliers, while success depends heavily on clinical trial outcomes and the ability to fund later-stage development and commercialization. Cross-border sourcing and operations also create foreign-exchange and supply-chain risk. - **Need for additional capital** [high] — Late-stage clinical development and potential commercialization require substantial funding. - **Clinical and regulatory failure** [critical] — Drug candidates may not meet efficacy, safety, or approval standards. - **Customer concentration** [high] — A small number of customers account for a substantial portion of revenue. - **Supplier dependence** [high] — The company relies on third-party suppliers and manufacturers for key inputs and production. - **Foreign exchange and cross-border disruption** [medium] — Purchases and operations span multiple countries and currencies. - Clinical trial failure could delay or eliminate value from Trappsol® Cyclo™ - Funding needs may be significant if development advances to commercialization - Revenue concentration leaves the company vulnerable to customer loss - Third-party supplier dependence creates supply and pricing risk - Regulatory and recall risk applies to medical devices and drug programs ## Accounting Investors should watch how the company accounts for clinical-stage development costs, acquired interests, and any impairment of long-lived or intangible assets. Revenue can be lumpy because a small number of customers drive a large share of sales, and segment results may change materially when subsidiaries are consolidated or assets are sold. Fair value judgments, equity-method or consolidation accounting, and impairment testing can all materially affect reported results. - **Research and development expense** — Affects operating loss and comparability across periods - **Consolidation of subsidiaries** — Can materially alter revenue, expenses, and segment mix - **Impairment of long-lived assets** — Could create non-cash charges and reduce carrying values - **Fair value measurements** — Can affect gains, losses, and balance-sheet carrying amounts - Clinical development spending is expensed as R&D and can swing sharply - Revenue concentration makes quarterly comparisons volatile - Consolidation of subsidiaries changes reported revenue and expenses - Impairment testing matters for long-lived assets and investments - Fair value estimates affect acquired interests and available-for-sale securities --- *Last updated: 2026-04-29T04:52:45.081428+00:00*